SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1228 participants.

Also called NCT06590012

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,228 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06590012
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06590012. Randomized; triple masking; primary purpose treatment. Start 2024-08-29 (actual); primary completion 2027-07-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY
Acronym
SIAT
Condition
Atherosclerosis
Condition
Atheroscleroses, Coronary
Condition
Carotid Atherosclerosis
Intervention (Drug)
Placebo
Intervention (Drug)
Tertinat
Lead sponsor
Institute for Atherosclerosis Research, Russia (class: other)

Record details

Record id
cardio:ct-nct06590012
Content hash
ad1953450161b18db21d5e3d37701814232a9c5a50b496bf026078db4141bfa8